Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
Cancers|October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple MyelomaAimaz Afrough, Shebli Atrash, Barry Paul, et al.
BMC Cancer|November 13, 2021
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review studyShebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, et al.
Ejhaem|July 18, 2022
Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary diseaseAl-Ola Abdallah, Ghulam Rehman Mohyuddin, Nausheen Ahmed, et al.
Cancers|January 10, 2026
Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter AnalysisPriyanka Venkatesh, Razan Mansour, Yara Shatnawi, et al.
Bone|September 24, 2018
FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patientsShebli Atrash, Isha Dua, Amy F Buros, et al.
Transplantation and Cellular Therapy|January 22, 2023
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple MyelomaHamza Hashmi, Shebli Atrash, Jayanshu Jain, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2022
Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review studyShebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, et al.
Cancers|December 11, 2025
Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled TrialsZain Alsaddi, Osama Younis, Ghena Khasawneh, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2025
Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM)Cindy Varga, Kip D Zimmerman, David M Foureau, et al.
European Journal of Haematology|February 8, 2023
Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myelomaAl-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, et al.
Pageof 9